glp-1 gip 2ra Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes The Emerging Role of Dual
Description
doi: 10.1016/s0014-5793(99)00145-3
In these trials, participants were randomized to receive a GLP-1 receptor agonist intervention at various doses and placebo plus usual care or standard care only as control groups
Once-daily oral semaglutide (Rybelsus) achieves an HbA 1c reduction of around 1115 mmol/mol in people with type 2 diabetes less than injectable semaglutide but comparable to other long-acting injectable GLP-1 RAs
Cost-effectivness of GLP-1 agonist use
The way through is to assign each measure an explicit job before the trial starts rather than after the results arrive
